Published in final edited form as:

Pharmacol Res. 2017 January ; 115: 1–13. doi:10.1016/j.phrs.2016.10.031.

Transcriptome Profiling of NIH3T3 Cell Lines Expressing Opsin and the P23H Opsin Mutant Identifies Candidate Drugs for the Treatment of Retinitis Pigmentosa

Yuanyuan Chen¹, Matthew J Brooks², Linn Gieser², Anand Swaroop², and Krzysztof Palczewski^{1,*}

¹Department of Pharmacology, Cleveland Center for Membrane and Structural Biology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106

²Neurobiology-Neurodegeneration & Repair Laboratory (N-NRL), National Eye Institute (NEI), National Institutes of Health (NIH), Bethesda, MD 20892

Abstract

Mammalian cells are commonly employed in screening assays to identify active compounds that could potentially affect the progression of different human diseases including retinitis pigmentosa (RP), a class of inherited diseases causing retinal degeneration with compromised vision. Using transcriptome analysis, we compared NIH3T3 cells expressing wildtype (WT) rod opsin with a retinal disease-causing single P23H mutation. Surprisingly, heterologous expression of WT opsin in NIH3T3 cells caused more than a 2-fold change in 783 out of 16,888 protein coding transcripts. The perturbed genes encoded extracellular matrix proteins, growth factors, cytoskeleton proteins, glycoproteins and metalloproteases involved in cell adhesion, morphology and migration. A different set of 347 transcripts was either up- or down-regulated when the P23H mutant opsin was expressed suggesting an altered molecular perturbation compared to WT opsin. Transcriptome perturbations elicited by drug candidates aimed at mitigating the effects of the mutant protein revealed that different drugs targeted distinct molecular pathways that resulted in a similar phenotype selected by a cell-based high-throughput screen. Thus, transcriptome profiling can provide essential information about the therapeutic potential of a candidate drug to restore normal gene expression in pathological conditions.

*CORRESPONDENCE to Krzysztof Palczewski, Ph.D., Department of Pharmacology, School of Medicine, Case Western Reserve University, 10900 Euclid Ave, Cleveland, Ohio 44106–4965, USA; Phone: 216–368–4631; Fax: 216–368–1300; kxp65@case.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ASSOCIATED CONTENT

Data access

The data presented in this publication have been deposited in NCBI's Gene Expression Omnibus [75] and are accessible through GEO Series accession number GSE77449 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77449>).

A temporary private link to give to reviewers and authors to access the submission is: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=qhgvkswelzwbhil&acc=GSE77449>

The Authors declare that they have no conflicts of interest with the contents of this article.

SUPPORTING INFORMATION

Quality control parameters of the RNA-seq data set and complete lists of transcripts that are differentially expressed among different sample groups.

Graphical abstract

Keywords

Rhodopsin; P23H opsin; retinitis pigmentosa; transcriptome; retina; drug discovery; cell-based HTS; transcriptome; RNA-seq

INTRODUCTION

Small molecules are the mainstay of pharmacotherapeutics for the treatment of human diseases. Such agents often are easy to administer, well tolerated by patients, and relatively inexpensive. Nonetheless, complex diseases remain difficult to manage, and typically worsen with age. In infectious diseases or cancer, poly-pharmacology aimed at diverse and unrelated targets can effectively deal with the primary problem but often with adverse side effects. This risk can be acceptable for treating terminal diseases or chronic life-threatening infections but not for slowly progressive diseases that are not fatal or overly burdensome during a patient's normal lifespan. To minimize such drug side effects, recent approaches in systems biology can be used to characterize the molecular features of disease models used in both the early and later stages of drug development [1, 2]. Moreover, these technologies can

be adapted to improve our understanding of the pharmacology of a starting molecule with respect to its possible off-target effects and therapeutic potential.

Retinitis pigmentosa (RP) is a progressive retinal degenerative disease associated with mutations in more than 50 genes [3, 4]. Effective treatments of RP are unavailable, even though gene therapy [5, 6] and pharmacological intervention with valproic acid [7-11] are currently undergoing clinical trials. The rhodopsin pigment, comprised of the protein opsin bound to a vitamin A chromophore that is regenerated in the endoplasmic reticulum and outer segment disc membranes, is an essential component of rod photoreceptor cells due to its pivotal role in phototransduction and its abundance in the photosensitive outer segments [12]. Thus, it is not surprising that *Rho* encoding the rod opsin, is the most frequent causal gene among autosomal dominant (ad) RP patients [3, 13]. The P23H mutation, observed in 10% of adRP cases, is a representative Class II mutation that causes opsin misfolding due to its thermal instability [3, 13-16]. Instability of P23H opsin leads to its progressive massive degradation in the rod photoreceptors of P23H knock-in mice [17, 18]. To rescue these photoreceptors, we hypothesized that improving P23H opsin stability could decrease photoreceptor cell death and improve vision. Alternatively, increasing the degradation of mutant opsin and leaving the WT rhodopsin allele to preserve visual function could be an equally viable therapeutic strategy for adRP. Thus, we developed and performed two sets of cell-based, small-molecule high-throughput screens (HTSs) to identify compounds that either improve the stability of the P23H opsin mutant or enhance its degradation [19]. Even though a valid photoreceptor cell line is unavailable, mammalian cells have been commonly used to study the biosynthesis of rhodopsin and to screen for drug candidates because the pre-ciliary biosynthesis of rhodopsin is generally shared by mammalian cells and rod photoreceptor cells [14, 20, 21]. In mammalian cell cultures, heterologously expressed WT opsin is located on the plasma membrane whereas P23H opsin accumulates in the endoplasmic reticulum (ER) due to its structural instability [14-16, 19-21].

For drug discovery, lead compounds identified from HTS in cell models are then tested in an animal model that represents the genetic defect and exhibits pathological signs seen in the corresponding human disease. The challenge of developing drug candidates showing efficacy in both cell and animal models sometimes lies in the dramatic difference of the two model systems. To improve our success rate of drug development, we need a better understanding of our disease models and the lead compounds' mechanisms of action. Advances in microarray and next generation sequencing (NGS)-based transcriptome profiling (RNA-seq) have already identified novel molecular pathways or key genes associated with the development of disease states in the mouse retina [22-30]. Although transcriptome studies have been applied to low-dose pharmacological treatments in disease models to evaluate drug efficacy and side effects [30-34], RNA-seq studies have rarely been used in the early stages of drug discovery to characterize the cell models used for high throughput screening and to investigate a lead compound's mechanism of action. [30, 35, 36].

Here, using high-throughput RNA-seq technology, we profiled the transcriptomes of three stable cell lines expressing either opsin/green fluorescent protein (GFP), P23Hopsin/GFP or GFP alone, under different treatment conditions. This study addresses three questions related

to drug discovery: 1) what are the general transcriptome changes in an established mammalian cell line due to heterologous expression of rod opsin; 2) what transcriptome changes arise from the expression of the P23H opsin mutant; and 3) what genes and associated molecular pathways are affected by treatment with active compounds selected from a HTS?

MATERIALS AND METHODS

Cells

NIH3T3 (WTopsin/GFP), NIH3T3 (P23Hopsin/GFP) and NIH3T3 (GFP) stable cell lines were generated by viral infection with pMiLRO, pMiLRO23 and pMXs-IG constructs, as previously published [19]. Mouse opsin or P23H opsin was co-expressed with GFP. When single clones were selected, no significant differences were observed between them with respect to cell shape, GFP fluorescence or localization of WT opsin (on the plasma membrane) or P23H opsin (in the ER) suggesting the defect of P23H opsin transport is not due to a clonal difference.

Immunostaining and fluorescence imaging

Immunostaining and fluorescence imaging followed published procedures [19]. Briefly, cells were seeded in a 384-well plate at 5,000 cells/well on day 1. These cells were treated with active compounds or a DMSO control on day 2. Cells were fixed with 4% paraformaldehyde 24 h after treatment. Rod opsin was immunostained with 1D4 monoclonal anti-rhodopsin antibody [37] followed by secondary labeling with Cy3-conjugated goat anti-mouse antibody (Jackson Immuno Research, West Grove, PA, USA). Nuclei were stained with DAPI. Fluorescence images were captured with an Operetta High Content Imaging System (Perkin Elmer, Waltham, MA, USA). Five images were taken from each well of the 384-well plate containing a total of 600-1000 cells. Three channels of fluorescence emission were used, Alexa488 (GFP), DAPI, and Cy3. Representative images of immunostained cells are shown in Figure 1A to F.

Image analysis

Only intact cell images were selected for analysis. The cytoplasm was defined by the GFP fluorescence of each cell with the cell boundary as the 0% line. Nuclei were visualized by DAPI fluorescence, and each nucleus, as defined by its edges, was assumed to comprise 50% of each cell. The membrane region was defined within -5 to 5% around the cell boundary, and the ER region was defined within 25 to 50% at the perinuclear region. Opsin staining on the plasma membrane was represented by the ratio of Cy3 intensity in the membrane region to that in the entire cell (MEM-total). Opsin staining in the ER region was denoted by the ratio of Cy3 intensity in the ER region to that in the entire cell (ER-total). MEM-total and ER-total were averaged from all the imaged intact cells in each well. Each condition was repeated in 3 or 8 wells, for treatments or controls, respectively. MEM-total and ER-total were then averaged from those biological repeats and presented as data points in Figure 1G to N. Error bars were standard deviations from those biological repeats.

Identification of active compounds by HTS

Compound 1 (an isoquinoline-2(3*H*)-hexanamide) and compound 2 (4-(5-chlorothiophen-2-yl)furan-2(5*H*)-one) were selected by a cell-based HTS of small molecules from the University of Cincinnati 2.5 K Diversity Set of Small-Molecules Library [19]. To identify small molecular compounds which rescue the P23H opsin mutant from ER retention, we performed a HTS with a β -galactosidase fragment complementation assay as described in reference [19]. Briefly, two complementary subunits of beta-galactosidase were individually fused with a plasma membrane-anchored peptide, the PH domain of phospholipase C delta (PLC), and the mouse opsin P23H mutant, respectively. A U2OS stable cell line was generated that consistently expresses these two fusion proteins. Due to its inherent instability, the P23H opsin fusion protein accumulates in the ER, whereas the PLC fusion protein remains anchored on the plasma membrane of cells. The separation of the two fusion proteins led to a complete lack of beta-galactosidase activity. Upon treatment with an active compound that stabilizes P23H opsin folding and transport to plasma membrane, two complementary beta-galactosidase subunits were colocalized on the plasma membrane resulting in a recovery of beta-galactosidase activity read by its luminescence. Using this cell-based assay in 384-well format, we screened the University of Cincinnati 2.5 K Diversity Set of small-molecules library and identified four hit compounds. An immunostaining and high-content imaging assay then was used to identify lead compounds with true activity. Both compound 1 and compound 2 increased the transport of the P23H opsin mutant to the plasma membrane, despite sharing little chemical or structural similarity.

Treatment of cell culture with active compounds

Each cell line was cultured at 37 °C with 5% CO₂ in Dulbecco's modified Eagle's medium (DMEM; Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone), 100 units/mL penicillin, 100 μ g/mL streptomycin, and 2.92 μ g/mL L-glutamine (Hyclone). The three cell lines were cultured to the same passage to achieve 90% confluence in a 50 mm culture dish before subsequent treatment. Five cell assay conditions were used: 1) NIH3T3(GFP) cells were treated with 0.05% DMSO, denoted as Control; 2) NIH3T3(WTopsin/GFP) cells were treated with 0.05% DMSO, denoted as Opsin; 3) NIH3T3(P23Hopsin/GFP) cells were treated with 0.05% DMSO, denoted as P23H; 4) NIH3T3(P23Hopsin/GFP) cells were treated with 5 μ M of compound 1, denoted as T1; 5) NIH3T3(P23Hopsin/GFP) cells were treated with 10 μ M of compound 2, denoted as T2. Each treatment condition was replicated in three 50 mm dishes. After 24 h of each treatment, the medium was aspirated, and cells were washed with phosphate-buffered saline (PBS, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄, pH 7.4, 137 mM NaCl, and 2.7 mM KCl) before being lysed.

RNA extraction

Cells were lysed with TRIzol (1 mL/dish, Thermo Fisher Scientific, Grand Island, NY, USA), and total RNA was extracted from each sample according to the TRIzol reagent manual [38, 39]. Extracted RNA samples were analyzed with a 2100 Bioanalyzer Nano chip (Agilent Technologies Genomics, Santa Clara, CA, USA) to assess total RNA quality (RIN: 10). RNA from each sample then was labeled and stored at -80 °C before RNA-seq analysis.

RNA-seq and data analyses

All transcript libraries were made with the TruSeq Stranded mRNA Sample Prep Kit (Illumina, San Diego, CA, USA). The 100 base paired samples were run on 2 lanes of a HiSeq 2500 Sequencing system (Illumina) with Rapid mode running RTAv1.18.61 software. Illumina adapter trimming was performed with Trimmomatic v0.33. Quality control (QC) was analyzed with FastQCv0.11.2 software. Reads were processed in parallel by both qualitative and quantitative analyses with multiple types of software including Bowtie2 v2.2.1, TopHat2 v2.0.11, Samtools v0.1.19, and eXpress v1.3.1, as previously described in Ref. [40] using the GRCm38 assembly and ENSEMBL v78 annotation. Expression analyses were performed with R v3.11. Principal component analysis was conducted to validate the reproducibility of replication (Table 1). TMM (trimmed mean of M-values) normalization was done with EdgeR v3.6.8 to normalize the count data in different samples that varied in depth. Differential expression (DE) was analyzed by limma v3.22.3 that employed the limma voom function for estimating dispersion [41]. For DE analysis, only transcripts wherein all replicates of any sample group were greater than 1 fragment per kilobase of transcript per million mapped reads (FPKM) were kept in the data set. FPKM values rather than count values were used to reduce length bias in transcript filtering. DE statistics were obtained by moderated t-test, Enhanced Bayes, and Benjamini-Hochberg calculations, yielding *P* values, F and B-statistics, and false discovery rates (FDRs), respectively. The DE filter was set for transcripts with FPKM fold changes of more than 2 and an FDR of less than 5%. Hierarchical clustering heatmaps were generated by Affinity Propagation employing the APcluster package in R using the Z-score of normalized FPKM values.

Gene ontology and biological process pathway analyses

Gene ontology (GO) analysis was initially performed with DAVID Bioinformatics Resources 6.7 (The Database for Annotation, Visualization and Integrated Discovery, <http://david.abcc.ncifcrf.gov/home.jsp>) [42, 43]. Functional Annotation Clustering was used only for the “Biological Processes” category at a GO level of 5 and greater. GO terms that had the lowest *P* values in each cluster as well as low FDR values were listed. The total number of genes included in all of the listed GO terms was considered to be 100%, and the number of genes in each GO term was calculated as a percentage in a pie chart for data visualization.

Reverse transcription and quantitative real-time polymerase chain reaction (qPCR)

RNA was extracted from cells and reverse transcribed into cDNA using the high capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA, USA) following the manufacturer's protocol. These cDNA samples were used as templates for qPCR. The qPCRs were performed using CYBR Green Super Mix (Bio-Rad Laboratories, Hercules, CA, USA). A total of 2 ng of cDNA was added to 10 μ L of CYBR Green Super Mix, 8 μ L of purified H₂O and 1 μ L of primers including forward and reverse primers at 10 μ M each. Each reaction therefore contained a 20 μ L solution in a single well of a 96-well PCR plate. We quantified 9 transcripts by qPCR using *Gapdh* as the control transcript. The 9 transcripts included: *Txnip*, *Nqo1*, *Gstp1*, *Pfdn6*, *Itch*, *Dnajb14*, *Vdr*, *Clec16a*, and *Masp1*. Specific bands of qPCR products were confirmed by DNA gel electrophoresis, stained with ethidium bromide and visualized by UV fluorescence. Primers for the 9 transcripts were: *Txnip*

(forward 5'-GTTGCGTAGACTACTGGGTGAAG-3'; reverse: 5'-CTCCTTTTTTGGCAGACACTGGTG-3'); *Nqo1* (forward: 5'-GCCGAACACAAGAAGCTGGAAG-3'; reverse: 5'-GGCAAATCCTGCTACGAGCACT-3'); *Gstp1* (forward: 5'-TGGAAGGAGGAGGTGGTTACCA-3'; reverse: 5'-GGTAAAGGGTGAGGTCTCCATC-3'); *Pfdn6* (forward: 5'-GATTACAGCGGTAGAGCGT-3'; reverse: 5'-TACTCAAGTCCTTCTGCAGCTGT-3'); *Itch* (forward: 5'-CTCGGATTACTCAGTGGGAAGAC-3'; reverse: 5'-GTTGCTCTTCTATTGTGGTCCAC-3'); *Vdr* (forward: 5'-GCTCAAACGCTGCGTGGACATT-3'; reverse: 5'-GGATGGCGATAATGTGCTGTTGC-3') *Dnajb14* (Forward: 5'-GCGCGCGCGTTATTGG-3'; reverse: 5'-CAGAAGTGCCGTCCTTTCCA-3'); *Dedd* (forward: 5'-CACACTTGGGAGCCAGCGAAAA-3'; reverse: 5'-AGCCGTCTCATGCTGGCAGTAT-3'); *Clec16a* (forward: 5'-GAACACCACAGACGAGGAGAAG-3'; reverse: 5'-CATACAGGAGGCAGAGCACGAA-3'); *Masp1* (forward: 5'-CCTTCAAAGACCAAGTGCTCGTC-3'; reverse: 5'-ACTCCATGCACCGTCCTTCAGA-3'); *Coro1b* (forward: 5'-CAGCCCCGAAATGTGCTTCTCAG-3'; reverse: 5'-GCAAAAGAGGCTGCCATTGTGG-3'); *Ttll1* (forward: 5'-ACCGGCTATTCTAGTGACGC-3'; reverse: 5'-GGGACACTGGTCAACACTCC-3'). Primers for *Gapdh* were: forward: 5'-TGGTGAAGCAGGC-3'; reverse: 5'-TGAAGTCGCAGGAGACAACC-3'. The fold change for each transcript was first normalized by *Gapdh*, and then compared to Control (NIH3T3 cells expressing GFP only). Fold changes were averaged from three biological replicates and error bars were from standard deviations of those replicates. *P* values comparing two conditions were calculated with the two-sample Student's *t*-test.

RESULTS

To discover effective small molecular drugs for retinitis pigmentosa associated with the rhodopsin P23H mutation, we previously undertook a cell-based HTS to identify small molecules rescuing the P23H opsin from misfolding and ER retention, using a beta-galactosidase complementation assay [19]. Briefly, using the complemented beta-galactosidase activity as a reporter, the amount P23H opsin successfully transported to the plasma membrane was quantified by its luminescence read from a microplate reader. In 384-well plates, we screened the University of Cincinnati 2.5 K Diversity Set of small-molecule library and identified compound 1 and compound 2 that featured outstanding potency as well as efficacy. Compound 1 (an isoquinoline-2(3H)-hexanamide) showed its EC₅₀ at 3.1 μM with an efficacy score of 87% whereas compound 2 ((4-(5-chlorothiophen-2-yl)furan-2(5H)-one)) had an EC₅₀ at 5.5 μM with an efficacy score of 166%. Both activity scores were normalized to 100% as exhibited by the effect of treatment with 5 μM 9-*cis*-retinal.

To confirm the activity of these two lead compounds for rescuing the transport of P23H opsin mutant from the ER to the plasma membrane, three stable NIH3T3 cell lines were

generated for the immunostaining and high-content imaging assay [19]. GFP was expressed, either with the opsin protein or by itself, as a positive selection marker to help generate the stable cell lines. In agreement with reports describing other mammalian cell models [14, 21, 44-49], the WT opsin protein localized to the plasma membrane of NIH3T3 cells as demonstrated by the staining of cellular boundaries, whereas the P23H opsin mutant accumulated in the perinuclear region with little plasma membrane staining indicating its predominant retention in the endoplasmic reticulum (ER) (Figure 1A-C). This mislocalization was noted in all clones of stable cells, suggesting the defect of P23H opsin transport is due to its structural instability, rather than an artificial clonal difference. To quantitatively compare the cellular localization of the WT and P23H opsins, we undertook an image-based analysis to quantify the immunostaining of opsin on the plasma membrane *versus* that in the ER relative to the total opsin staining in each cell (MEM-total *versus* ER-total, Figure 1). For controls, quantitative analysis of 8 biological repeats, each calculated from images of 600-1000 cells, provided reliable baselines representing “normal” and “aberrant” conditions. In agreement with what was observed from the images in Figure 1B and C, relative staining of WT opsin was significantly higher on the plasma membrane (MEM-total=0.20, Figure 1G), and lower in the ER (ER-total=0.27, Figure 1K), as compared to P23H opsin staining.

Two small molecular compounds were found from the HTS which rescued transport of P23H opsin from the ER to the plasma membrane. Treatment with compound 1 resulted in a reproducible redistribution of P23H opsin throughout the cell body (Figure 1D), with a dose-dependent increase in cell boundary staining (MEM-total increased from 0.10 up to 0.14, EC_{50} =0.48 μ M, Figure 1H), but little change in the ER region (Figure 1L). Comparably, treatment with compound 2 also increased the plasma membrane staining of P23H opsin (MEM-total increased from 0.10 to 0.16, EC_{50} =7.5 μ M, Figure 1E and I), whereas its perinuclear staining was reduced in a dose dependent manner (ER-total decreased from 0.36 to 0.31, EC_{50} =6.1 μ M, Figure 1M). Interestingly, co-treatment with both compounds produced a significant improvement of P23H opsin transport to the plasma membrane (MEM-total increased from 0.12 up to 0.20, EC_{50} =5.2 μ M, Figure 1J), which also dramatically reduced the perinuclear accumulation of the opsin mutant (ER-total decreased from 0.36 to 0.27, EC_{50} =8.1 μ M, Figure 1N). The differing cellular distribution of P23H opsin upon treatment with these two compounds and their synergic effect suggest that they utilize distinct cellular targets.

To understand the effect of heterologous expression of opsin or the P23H mutant and the molecular events altered by treatment with compounds 1 and 2, we profiled the transcriptomes of different sample groups. Principle component analysis showed the consistency between repeats of each sample group (Figure 2A and Table 1). Protein-coding transcripts with fold changes of more than 2 and a false discovery rate (FDR) less than 5% were collected in each DE profile of two cellular conditions. FPKM reads of *Rho* transcripts from NIH3T3 cells expressing WT opsin and NIH3T3 cells expressing the P23H opsin mutant were similar (Figure 2B), suggesting that the changes in transcripts between the two cell lines were not due to differential expression of the *Rho* transgenes.

Heterologous expression of opsin and its mutants in mammalian cells has been used extensively to study rhodopsin biochemistry and identify drug candidates [14, 20, 21, 44-48]. However, it is unknown whether expression of opsin produces a transcriptome change within the host cell line and if analysis of changes in the transcriptome could be used for validation of lead compounds from HTS. Here, a total of 783 out of 16,888 protein coding transcripts revealed differential expression in Opsin *versus* Control cell lines (Figure 2C). Notably, many of the perturbed genes are relevant to pathways involved in cell adhesion, morphology and migration and encode extracellular matrix proteins, growth factors, cytoskeleton proteins, glycoproteins or metalloproteases (Efemp1, Adamts1, Col8a1, Col11a1, Calhm2, Loxl4, Tgfbi, Jam3, Angptl2, Kitl, Gpnmb, Neo1, Dcn, Prl2c2 and Prl2c3) (Figure 3A). These changes in expression could represent a stress response due to the heterologous expression of opsin in NIH3T3 cells, which are fibroblasts that feature elevated expression of extracellular matrix proteins [35, 50, 51]. Among other significantly altered genes, some are involved in transcriptional regulation or RNA splicing (*Zfp518a*, *Hnmph1*, *Sp140*, *Ankrd1* and *Mef2c*), and others participate in cellular responses to oxidative stress (*Srxn1*, *Prdx5*), protein glycosylation (*Prmt1*), and lipid transport (*Vldlr*). Their changes could be due to cellular adaptation required to support the biosynthesis of the opsin protein, a G protein-coupled receptor (GPCR). Alternatively, the DE profile of Opsin *versus* Control cells includes many genes containing cAMP responsive elements (CREs) [52] which could be regulated by the leaky activity of free opsin [53-55] coupled to endogenous G_{i/o} protein signaling [7, 16, 56]. Such genes include but are not limited to *Gsta4*, *Pcx*, and *Pdk4* involved in metabolic processes; *Per1*, *Ppargc1a* and *Egfr1* that regulate gene transcription; the growth factor *Prl2c2*, the neurotransmitter *Inhba*; and *Ppp1r15a* involved in DNA repair (Table 2). A more complete evaluation of biological processes affected by the expression of opsin in NIH3T3 cells is presented in Figure 3B.

P23H opsin revealed a transcriptome shift compared to WT opsin expressed in NIH3T3 cells. We identified 347 differentially expressed genes from the DE profile of P23H *versus* control, indicating that far fewer genes were affected by expression of the mutant opsin (Figure 2C). A total of 176 of these genes showed differential expression in both Opsin *versus* Control and P23H *versus* Control, and among these, 159 genes evidenced the same trend. These similar changes could result from common structural and biochemical properties shared by P23H opsin and WT opsin. GO analysis of these genes revealed a significant enrichment of genes involved in the vesicle transport pathway, such as *Klc1*, *Stx16*, *Kif1c*, *Myo7a*, *Dlg4* and *Lrp8* (Table 3). Transcripts involved in metabolism, apoptosis, and transcription pathways were similarly changed in both DE profiles of Opsin *versus* Control and P23H *versus* Control.

To assess transcriptome differences between the disease and control models, we compared the DE profiles of P23H *versus* Opsin that identified 330 transcripts (Figure 4A). Among these transcripts, 271 were not seen in the DE profile of P23H *versus* Control, but did show up in the profile of Opsin *versus* Control. This result suggests that 84% of the transcripts that displayed differential expression in P23H *versus* Opsin are altered due to molecular perturbations induced by the expression of WT opsin but not P23H opsin. This result could be due to the significant reduction of folded P23H opsin protein as a result of its ER accumulation and its enhanced degradation in these NIH3T3 cells [19]. GO analysis showed

significant enrichment in genes involved in cell adhesion (P value = 0.00004 and Benjamini = 0.06), including *Col8a1*, *Col16a1*, *Col11a1*, *Cdh18*, *Cdh11a*, *Pcdhb1*, *Pcdhb17*, *Pcdhb21*, *Pcdh1*, *Alcam*, *Ncam*, *Fn1*, and *Jam3* (Figure 4A, genes denoted in black).

Apart from genes revealing the lost transcriptional perturbation by the P23H opsin mutant, there were 59 genes observed in DE profiles of both P23H *versus* Control and P23H *versus* Opsin, suggesting that these changes resulted from the aberrant properties of the P23H opsin mutant. These genes can be classified as participating in: 1) cell adhesion (*Thbs1*, *Napsa*, *Vcan*); 2) cell differentiation (*Vdr*, *Eya1*, *Spr1a*, *Nrp*, *Egln3*); 3) membrane protein biosynthesis (*Galnt13*, *Fam69b*); 4) lipid transport (*Apol10b*); and 5) glycoprotein degradation (*Lyz2*) (Figure 4A, genes denoted in red). Activation of the ER-associated degradation (ERAD) pathway has been reported in the P23H knock-in mouse model [57] and in mammalian cell models transfected with P23H opsin [21, 58]. However, genes related to ERAD did not change significantly in NIH3T3 cells upon continuous expression of either WT opsin or the P23H opsin mutant (Table 4). Molecular chaperones including calnexin, BIP/Grp78 and GRP94 were reported to directly associate with P23H opsin in cell cultures [49, 59], and EDEM1 was reported to be responsible for the initiation of the ERAD of P23H opsin [60]. Here we observed a slight upregulation of molecular chaperones including *Hspa5* (*Bip*), *Hsp90b1* (*Grp94*), *Edem2* and *Calr* (encoding calreticulin) but not *Edem1* or *Canx* (encoding calnexin) in cells expressing P23H opsin compared to those expressing WT opsin. These data suggest that the instability of P23H opsin could have moderately induced molecular chaperones to maintain protein homeostasis (Figure 4B). However, no significant changes of other ERAD genes (*Atf4*, *Atf6*, *Ern1* (*Ire1*), *Eif2ak3*, *Eif2a* or *Ddit* (*Chop*)) were observed in DE profiles of P23H *versus* Opsin (Figure 4B), suggesting that NIH3T3 cells can be intrinsically adapted to protein misfolding. Moreover, no significant induction of caspase expression was seen in DE profiles of P23H *versus* Opsin. Due to differences between immortalized NIH3T3 cells and mouse photoreceptors [61, 62], transcriptome changes in a cell line should be interpreted with caution and cannot be directly correlated with the molecular events that occur in a mouse bearing the P23H mutation. Rather, to understand the molecular events involved in photoreceptor death, transcriptomes derived from mouse retina at an early age before photoreceptor death occurs should be compared between wild type and heterozygous P23H knock-in animals. But here, our goal of comparing transcriptomes between these cell lines was to obtain information pertinent to drug discovery through early stage analyses of molecular events following various treatments.

Thus, we identified two active compounds through a cell-based, small molecule HTS, both of which rescued the transport of P23H opsin back from the ER to the plasma membrane. Each compound produced a different distribution pattern for the P23H opsin and co-treatment with both resulted in a synergistic rescue of P23H opsin homeostasis (Figure 1). These results suggest that these two active compounds target different cellular pathways which culminate in a similar cellular effect. Such affected pathways can be revealed by cellular transcriptome changes that are sensitive to perturbations of cellular conditions. To delineate the molecular events initiated by each of these compounds, we compared the DE profiles of T1 *versus* P23H and T2 *versus* P23H (Figure 5). The DE profile of T1 *versus* P23H recorded 2,715 changed transcripts, whereas that of T2 *versus* P23H showed no

significant changes. These transcriptome changes were captured 24 h after treatments when rescue of P23H opsin transport was first observed (Figure 1D and E). Therefore, this finding suggests that the rescue of P23H opsin transport by T1 could primarily result from transcriptional regulation, whereas compound 2 could directly target the P23H opsin protein or other proteins that improve the folding or transport of the opsin mutant without directly affecting transcription.

The transcriptional impact of treatment with compound 1 (T1) was profound, causing a greater than 16% change in the transcriptome (Figure 5A). Due to the large number of transcripts affected by T1, these transcripts were initially grouped as either up- or down-regulated before the GO analysis. Biological processes affected by T1 then were classified (Figure 5C). Among the enriched pathways, genes involved in vesicle-mediated transport (2%), regulation of microtubule cytoskeleton organization (2%), and regulation of protein modifications (3%) correlated with the improved P23H opsin transport observed by immunostaining (compare Figure 1D with 5C). Notably, 117 genes were reversed in the DE profile of T1 *versus* P23H compared to the DE profile of P23H *versus* Opsin (Figure 5B), suggesting these affected genes by P23H opsin were somehow “corrected” by T1. Correlating with the observation that T1 partially rescued the transport of the P23H opsin, changes of these transcripts by T1 could involve pathways either causing or being effected by the rescued P23H opsin transport. These genes were manually classified according to their biological functions documented in the Gene Cards Human Gene Database (<http://www.genecards.org>) (Figure 5D). The top 25 up- and down-regulated transcripts with known functions are listed next to their classifications. The most relevant biological processes to P23H opsin biosynthesis include, but are not limited to those regulating cytoskeleton dynamics, vesicle transport, protein folding and ERAD, as well as a response to oxidative stress. Among transcripts responding to oxidative stress, *Gstp1* and *Nqo1* were down-regulated in P23H *versus* Opsin and up-regulated in T1 *versus* P23H. These genes protect cells from reactive oxygen species generated during protein biosynthesis by transferring thiol groups for disulfide bonds [63]. Up-regulation of *Gstp1* and *Nqo1* could represent an elevated response to reactive oxygen species that is frequently correlated with protein misfolding. Notably, molecular chaperones *Dnajb14* and *Pfdn6* (prefoldin), both involved in protein folding and ERAD, were down-regulated in P23H and reversed by T1. Expression of *Dnajb14* was reported to accelerate the degradation of misfolded membrane proteins such as the cystic fibrosis transmembrane conductance regulator 508 (CFTR 508) [64]. Prefoldins were previously reported to prevent ubiquitinated-protein aggregation under ER-stress [65-67]. Up-regulation of these two molecular chaperones can be correlated with the improved homeostasis of P23H opsin in NIH3T3 cells. The same trend of changes was confirmed by qPCR (Figure 6; Table 5). Collectively, this study identified candidate genes for further investigation to attain a better understanding of the molecular targets of T1 and its affected pathways that can improve the homeostasis of misfolded opsin mutants.

In contrast to the profound transcriptome shift by T1, the lack of transcriptome alterations by treatment with compound 2 (T2) suggests that, in addition to transcriptome analysis, other systems biology techniques such as proteomics [68] are also needed for compound-target profiling. Recent work on a truncated mutant of CFTR (F508) clearly demonstrates that a

global interactome remodeling occurs to CFTR interacting partners which are crucial for membrane localization [69].

DISCUSSION

We have identified two small molecular compounds that rescued the transport of a disease-causing P23H opsin mutant in a mammalian stable cell line. Though the synergistic effect of these two compounds supports their distinctive molecular targets, it is still unclear as to which molecular pathways were affected by their treatment. In attempting to answer this question, we report several observations after analyzing the transcriptomes of stable cell lines expressing WT or P23H opsin that we had used for discovering drugs for the treatment of retinitis pigmentosa [19]. First, we have shown that cell lines used for drug discovery should be profiled to appreciate their advantages and limitations as disease models. Second, we demonstrated that techniques associated with approaches in systems biology such as transcriptome profiling can be developed as a standard procedure for compound profiling at early stages of drug discovery to guide further investigation of lead compounds' mechanisms of action. Whereas treatment with compound 1 reversed 117 transcripts that were "abnormally" expressed due to aberrant P23H opsin, treatment with compound 2 did not affect the transcriptome of cells expressing the P23H opsin. This finding confirmed that these two compounds have distinct mechanisms of action, even though treatment with each compound resulted in a partially rescued transport of P23H opsin. Transcriptome analysis already is used routinely to study molecular events during both the development of the normal retina and the onset and progression of degenerative retinal diseases. It will not be too long before this technique is broadly employed during drug discovery for treatment of such diseases.

Treatment with two active compounds caused distinct transcriptome changes. RNA-seq-based transcriptome analysis has been used to examine the efficacy of potential drugs for diabetic retinopathy in a mouse model [30]. A recent study used microarray analysis to examine the pathways changed by small molecular agents that could prevent staurosporine-induced apoptosis of NIH3T3 cells [35]. The transcriptome analysis of control and treated cells identified changes in gene expression affected by apoptotic conditions that could be reversed by treatment with drugs used in the screen.

Modern genetic profiling can enhance systems pharmacology in the endeavor to improve the design of drugs and their testing in models of complex human diseases. First, genetic profiling can provide a global assessment of the alterations in signaling systems caused by disease. Any perturbation of a native state, even resulting from a single mutation, can alter many cellular networks to induce a new steady-state that then is manifested as a disease phenotype. For example, removal of the retina-specific leucine zipper gene, *Nrl* [70] alters hundreds of transcripts that change the photoreceptor population [28, 29, 71]. Similarly, mice with a genetic A/J background exhibit variations in hundreds of transcripts compared to C57Bl/6J WT mice, driving complex alterations associated with cone photoreceptor cell degeneration [72]. Modern genetic profiling also can determine how well a therapy returns an abnormal gene expression landscape toward more normal conditions. In this study, we showed that treatment with compound 1 regulated transcripts involved in multiple pathways

related to membrane protein biosynthesis and transport. These effects can be viewed as desirable activities of compound 1. In contrast, transcripts affected by compound 1 that relate to cell cycle and apoptosis could be counted as risk factors that should be tested in animal models for potential side effects. Connections between various intra- and inter-cellular pathways must be considered when evaluating drug safety and efficacy and even the duration of a successful therapy. Thus, the initial specificity of a drug does not guarantee its long-term effectiveness or safety. Rather, genetic profiling can assess the molecular consequences in multiple cell-types associated with a particular drug treatment and thereby improve ultimate drug design [73].

The transcriptome changes observed in NIH3T3 cells with rod opsin expression could be specific to this cell line and have little direct correlation with free rod opsin signaling in photoreceptor cells *in vivo* ^{37, 58, 59}. However, the DE profile of Opsin *versus* Control is a transcriptional measure of the molecular properties induced by WT opsin in NIH3T3 cells that can be compared to the DE profile of P23H *versus* Control (Table 3). This finding could link the cause, namely the P23H single mutation, with its consequences, i.e. ER retention of P23H opsin in these cells. Notably, even though NIH3T3 cells lack the photoreceptor cell's tertiary outer segment ciliary structure, the pre-ciliary biosynthesis of opsin is similar in both types of cells. The defect of P23H opsin transport is due to its structural instability and ER retention, a pre-ciliary defect. Therefore, the transcriptome difference between the two stable cell lines expressing the WT or P23H opsin, in parallel to the transcriptome difference between WT or P23H knock-in mouse models, provides an essential set of data to understand the advantages and limitations of cells used for drug discovery .

In short, uncommonly used in small molecular screening, we employed NGS to evaluate a simple cellular system as a disease model for drug discovery. This strategy can then be tailored to identify novel and effective compounds or combinations of compounds applicable to the treatment of complex diseases as recently reported in animal models [74] and eventually in humans.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

We thank Dr. Leslie T. Webster, Jr., and all members of the Palczewski laboratory (Case Western Reserve University) for valuable comments regarding this manuscript. This work utilized the computational resources of the HPC Biowulf cluster at NIH (<http://hpc.nih.gov>). K.P. is the John H. Hord Professor of Pharmacology.

Funding Information

This research was supported in part by grants from the National Institutes of Health (NIH) (EY022326 and EY R24024864 to K.P and K99 EY024992 to Y.C.), the Arnold and Mabel Beckman Foundation, Foundation Fighting Blindness, and the Intramural Research Program of the National Eye Institute (EY000474 and EY000546 to A.S.).

ABBREVIATIONS

ad autosomal dominant

BP	biological process
CHOP	C/EBP homologous protein
CRE	the cAMP-responsive element
CREB	the cAMP-responsive element-binding protein
CREM	the cAMP-responsive element modulator
ATF-1	activating transcription factor-1
DAVID	the database for annotation, visualization and integrated discovery
DE	differential expression
DMEM	Dulbecco's modified Eagle's medium
ER	endoplasmic reticulum
ERAD	ER-associated protein degradation
FDA	Food and Drug Administration
FDR	false discovery rate
FPKM	fragments per kilobase of transcript per million mapped reads
GFP	green fluorescence protein
GPCR	G protein-coupled receptor
GO	gene ontology
HTS	high-throughput screen or screening
NGS	next-generation sequencing
qPCR	quantitative real-time polymerase chain reaction
RP	retinitis pigmentosa
WT	wild-type

REFERENCES

1. Boland MR, Jacunski A, Lorberbaum T, Romano JD, Moskovitch R, Tatonetti NP. Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms. Wiley interdisciplinary reviews. Systems biology and medicine. 2015
2. Westerhoff HV, Nakayama S, Mondeel TD, Barberis M. Systems Pharmacology: An opinion on how to turn the impossible into grand challenges. Drug discovery today. Technologies. 2015; 15:23–31. [PubMed: 26464087]
3. Daiger SP, Sullivan LS, Bowne SJ. Genes and mutations causing retinitis pigmentosa. Clinical genetics. 2013; 84(2):132–41. [PubMed: 23701314]

4. Ratnapriya R, Swaroop A. Genetic architecture of retinal and macular degenerative diseases: the promise and challenges of next-generation sequencing. *Genome Med.* 2013; 5(10):84. [PubMed: 24112618]
5. LaVail MM, Yasumura D, Matthes MT, Yang H, Hauswirth WW, Deng WT, Vollrath D. Gene Therapy for MERTK-Associated Retinal Degenerations. *Advances in experimental medicine and biology.* 2016; 854:487–93. [PubMed: 26427450]
6. Conlon TJ, Deng WT, Erger K, Cossette T, Pang JJ, Ryals R, Clement N, Cleaver B, McDoom I, Boye SE, Peden MC, Sherwood MB, Abernathy CR, Alkuraya FS, Boye SL, Hauswirth WW. Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. *Human gene therapy. Clinical development.* 2013; 24(1): 23–8. [PubMed: 23692380]
7. Kumar A, Midha N, Gogia V, Gupta S, Sehra S, Chohan A. Efficacy of oral valproic acid in patients with retinitis pigmentosa. *Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.* 2014; 30(7):580–6.
8. Bhalla S, Joshi D, Bhullar S, Kasuga D, Park Y, Kay CN. Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid. *The British journal of ophthalmology.* 2013; 97(7):895–9. [PubMed: 23603755]
9. Shanmugam PM, Minija CK, Ramanjulu R, Tekwani P, Saxena M. Effect of short-term oral valproic Acid on vision and visual field in retinitis pigmentosa. *Ophthalmology and therapy.* 2012; 1(1):6. [PubMed: 25135586]
10. Sisk RA. Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa. *The British journal of ophthalmology.* 2012; 96(8):1154–5. [PubMed: 22581401]
11. Clemson CM, Tzekov R, Krebs M, Checchi JM, Bigelow C, Kaushal S. Therapeutic potential of valproic acid for retinitis pigmentosa. *The British journal of ophthalmology.* 2011; 95(1):89–93. [PubMed: 20647559]
12. Palczewski K. Chemistry and biology of vision. *The Journal of biological chemistry.* 2012; 287(3): 1612–9. [PubMed: 22074921]
13. Sung CH, Davenport CM, Hennessey JC, Maumenee IH, Jacobson SG, Heckenlively JR, Nowakowski R, Fishman G, Gouras P, Nathans J. Rhodopsin mutations in autosomal dominant retinitis pigmentosa. *Proc. Natl. Acad. Sci. U. S. A.* 1991; 88(15):6481–5. [PubMed: 1862076]
14. Sung CH, Schneider BG, Agarwal N, Papermaster DS, Nathans J. Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. *Proceedings of the National Academy of Sciences of the United States of America.* 1991; 88(19):8840–4. [PubMed: 1924344]
15. Noorwez SM, Kuksa V, Imanishi Y, Zhu L, Filipek S, Palczewski K, Kaushal S. Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. *The Journal of biological chemistry.* 2003; 278(16): 14442–50. [PubMed: 12566452]
16. Chen Y, Jastrzebska B, Cao P, Zhang J, Wang B, Sun W, Yuan Y, Feng Z, Palczewski K. Inherent instability of the retinitis pigmentosa P23H mutant opsin. *The Journal of biological chemistry.* 2014; 289(13):9288–303. [PubMed: 24515108]
17. Sakami S, Maeda T, Bereta G, Okano K, Golczak M, Sumaroka A, Roman AJ, Cideciyan AV, Jacobson SG, Palczewski K. Probing mechanisms of photoreceptor degeneration in a new mouse model of the common form of autosomal dominant retinitis pigmentosa due to P23H opsin mutations. *The Journal of biological chemistry.* 2011; 286(12):10551–67. [PubMed: 21224384]
18. Sakami S, Kolesnikov AV, Kefalov VJ, Palczewski K. P23H opsin knock-in mice reveal a novel step in retinal rod disc morphogenesis. *Human molecular genetics.* 2014; 23(7):1723–41. [PubMed: 24214395]
19. Chen Y, Tang H, Seibel W, Papoian R, Li X, Lambert NA, Palczewski K. A High-Throughput Drug Screening Strategy for Detecting Rhodopsin P23H Mutant Rescue and Degradation. *Investigative ophthalmology & visual science.* 2015; 56(4):2553–67. [PubMed: 25783607]
20. Mendes HF, Cheetham ME. Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa. *Human molecular genetics.* 2008; 17(19): 3043–54. [PubMed: 18635576]

21. Saliba RS, Munro PM, Luthert PJ, Cheetham ME. The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. *Journal of cell science*. 2002; 115(Pt 14):2907–18. [PubMed: 12082151]
22. Uren PJ, Lee JT, Doroudchi MM, Smith AD, Horsager A. A profile of transcriptomic changes in the rd10 mouse model of retinitis pigmentosa. *Molecular vision*. 2014; 20:1612–28. [PubMed: 25489233]
23. Sundermeier TR, Vinberg F, Mustafi D, Bai X, Kefalov VJ, Palczewski K. R9AP overexpression alters phototransduction kinetics in iCre75 mice. *Investigative ophthalmology & visual science*. 2014; 55(3):1339–47. [PubMed: 24526444]
24. Alves CH, Bossers K, Vos RM, Essing AH, Swagemakers S, van der Spek PJ, Verhaagen J, Wijnholds J. Microarray and morphological analysis of early postnatal CRB2 mutant retinas on a pure C57BL/6J genetic background. *PloS one*. 2013; 8(12):e82532. [PubMed: 24324803]
25. Yu J, Farjo R, MacNee SP, Baehr W, Stambolian DE, Swaroop A. Annotation and analysis of 10,000 expressed sequence tags from developing mouse eye and adult retina. *Genome Biol*. 2003; 4(10):R65. [PubMed: 14519200]
26. Roger JE, Hiriyanna A, Gotoh N, Hao H, Cheng DF, Ratnapriya R, Kautzmann MA, Chang B, Swaroop A. OTX2 loss causes rod differentiation defect in CRX-associated congenital blindness. *The Journal of clinical investigation*. 2014; 124(2):631–43. [PubMed: 24382353]
27. Yang HJ, Ratnapriya R, Cogliati T, Kim JW, Swaroop A. Vision from next generation sequencing: multi-dimensional genome-wide analysis for producing gene regulatory networks underlying retinal development, aging and disease. *Progress in retinal and eye research*. 2015; 46:1–30. [PubMed: 25668385]
28. Akimoto M, Cheng H, Zhu D, Brzezinski JA, Khanna R, Filippova E, Oh EC, Jing Y, Linares JL, Brooks M, Zarepari S, Mears AJ, Hero A, Glaser T, Swaroop A. Targeting of GFP to newborn rods by Nrl promoter and temporal expression profiling of flow-sorted photoreceptors. *Proc. Natl. Acad. Sci. U. S. A.* 2006; 103(10):3890–5. [PubMed: 16505381]
29. Brooks MJ, Rajasimha HK, Roger JE, Swaroop A. Next-generation sequencing facilitates quantitative analysis of wild-type and Nrl(–/–) retinal transcriptomes. *Mol. Vis*. 2011; 17:3034–54. [PubMed: 22162623]
30. Kandpal RP, Rajasimha HK, Brooks MJ, Nellisery J, Wan J, Qian J, Kern TS, Swaroop A. Transcriptome analysis using next generation sequencing reveals molecular signatures of diabetic retinopathy and efficacy of candidate drugs. *Mol. Vis*. 2012; 18:1123–46. [PubMed: 22605924]
31. Das A, Chai JC, Yang CS, Lee YS, Das ND, Jung KH, Chai YG. Dual transcriptome sequencing reveals resistance of TLR4 ligand-activated bone marrow-derived macrophages to inflammation mediated by the BET inhibitor JQ1. *Scientific reports*. 2015; 5:16932. [PubMed: 26582142]
32. Sakuma K, Komatsu H, Maruyama M, Imaichi S, Habata Y, Mori M. Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain. *PloS one*. 2015; 10(2):e0118510. [PubMed: 25693194]
33. Giordano E, Davalos A, Crespo MC, Tome-Carneiro J, Gomez-Coronado D, Visioli F. Soy isoflavones in nutritionally relevant amounts have varied nutrigenomic effects on adipose tissue. *Molecules*. 2015; 20(2):2310–22. [PubMed: 25647572]
34. Tavares R, Scherer NM, Ferreira CG, Costa FF, Passetti F. Splice variants in the proteome: a promising and challenging field to targeted drug discovery. *Drug discovery today*. 2015; 20(3): 353–60. [PubMed: 25462533]
35. Wu J, Wang Y, Liang S, Ma H. Cytoprotective effect of selective small-molecule caspase inhibitors against staurosporine-induced apoptosis. *Drug design, development and therapy*. 2014; 8:583–600.
36. Palfreyman MG, Hook DJ, Klimczak LJ, Brockman JA, Evans DM, Altar CA. Novel directions in antipsychotic target identification using gene arrays. *Curr. Drug Targets CNS Neurol. Disord*. 2002; 1(2):227–38. [PubMed: 12769629]
37. Hodges RS, Heaton RJ, Parker JM, Molday L, Molday RS. Antigen-antibody interaction. Synthetic peptides define linear antigenic determinants recognized by monoclonal antibodies directed to the cytoplasmic carboxyl terminus of rhodopsin. *J. Biol. Chem*. 1988; 263(24):11768–75. [PubMed: 2457026]

38. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. *BioTechniques*. 1993; 15(3):536–7.
39. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Analytical biochemistry*. 1987; 162(1):156–9. [PubMed: 2440339]
40. Kaewkhaw R, Kaya KD, Brooks M, Homma K, Zou J, Chaitankar V, Rao M, Swaroop A. Transcriptome Dynamics of Developing Photoreceptors in Three-Dimensional Retina Cultures Recapitulates Temporal Sequence of Human Cone and Rod Differentiation Revealing Cell Surface Markers and Gene Networks. *Stem Cells*. 2015; 33(12):3504–18. [PubMed: 26235913]
41. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic acids research*. 2015; 43(7):e47. [PubMed: 25605792]
42. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature protocols*. 2009; 4(1):44–57. [PubMed: 19131956]
43. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic acids research*. 2009; 37(1):1–13. [PubMed: 19033363]
44. Krebs MP, Holden DC, Joshi P, Clark CL 3rd, Lee AH, Kaushal S. Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue. *Journal of molecular biology*. 2010; 395(5):1063–78. [PubMed: 19913029]
45. Mendes HF, Zaccarini R, Cheetham ME. Pharmacological manipulation of rhodopsin retinitis pigmentosa. *Advances in experimental medicine and biology*. 2010; 664:317–23. [PubMed: 20238031]
46. Ohgane K, Dodo K, Hashimoto Y. Retinobenzaldehydes as proper-trafficking inducers of folding-defective P23H rhodopsin mutant responsible for retinitis pigmentosa. *Bioorganic & medicinal chemistry*. 2010; 18(19):7022–8. [PubMed: 20805032]
47. Zhu L, Imanishi Y, Filipek S, Alekseev A, Jastrzebska B, Sun W, Saperstein DA, Palczewski K. Autosomal recessive retinitis pigmentosa and E150K mutation in the opsin gene. *The Journal of biological chemistry*. 2006; 281(31):22289–98. [PubMed: 16737970]
48. Jiang H, Xiong S, Xia X. Retinitis pigmentosa-associated rhodopsin mutant T17M induces endoplasmic reticulum (ER) stress and sensitizes cells to ER stress-induced cell death. *Molecular medicine reports*. 2014; 9(5):1737–42. [PubMed: 24573320]
49. Anukanth A, Khorana HG. Structure and function in rhodopsin. Requirements of a specific structure for the intradiscal domain. *J. Biol. Chem*. 1994; 269(31):19738–44. [PubMed: 8051054]
50. Leibiger C, Kosyakova N, Mkrtchyan H, Gleis M, Trifonov V, Liehr T. First molecular cytogenetic high resolution characterization of the NIH 3T3 cell line by murine multicolor banding. *The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society*. 2013; 61(4):306–12. [PubMed: 23321776]
51. Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. *The Journal of cell biology*. 1963; 17:299–313. [PubMed: 13985244]
52. Kim HJ, Son ED, Jung JY, Choi H, Lee TR, Shin DW. Violet light down-regulates the expression of specific differentiation markers through Rhodopsin in normal human epidermal keratinocytes. *PloS one*. 2013; 8(9):e73678. [PubMed: 24069221]
53. Cornwall MC, Fain GL. Bleached pigment activates transduction in isolated rods of the salamander retina. *The Journal of physiology*. 1994; 480(Pt 2):261–79. [PubMed: 7532713]
54. Cornwall MC, Matthews HR, Crouch RK, Fain GL. Bleached pigment activates transduction in salamander cones. *The Journal of general physiology*. 1995; 106(3):543–57. [PubMed: 8786347]
55. Buczylo J, Saari JC, Crouch RK, Palczewski K. Mechanisms of opsin activation. *The Journal of biological chemistry*. 1996; 271(34):20621–30. [PubMed: 8702809]
56. Jastrzebska B, Chen Y, Orban T, Jin H, Hofmann L, Palczewski K. Disruption of Rhodopsin Dimerization with Synthetic Peptides Targeting an Interaction Interface. *The Journal of biological chemistry*. 2015; 290(42):25728–44. [PubMed: 26330551]

57. Chiang WC, Kroeger H, Sakami S, Messah C, Yasumura D, Matthes MT, Coppinger JA, Palczewski K, LaVail MM, Lin JH. Robust Endoplasmic Reticulum-Associated Degradation of Rhodopsin Precedes Retinal Degeneration. *Molecular neurobiology*. 2015; 52(1):679–95. [PubMed: 25270370]
58. Mendes HF, van der Spuy J, Chapple JP, Cheetham ME. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. *Trends Mol. Med.* 2005; 11(4):177–85. [PubMed: 15823756]
59. Noorwez SM, Sama RR, Kaushal S. Calnexin improves the folding efficiency of mutant rhodopsin in the presence of pharmacological chaperone 11-cis-retinal. *J. Biol. Chem.* 2009; 284(48):33333–42. [PubMed: 19801547]
60. Kosmaoglou M, Kanuga N, Aguila M, Garriga P, Cheetham ME. A dual role for EDEM1 in the processing of rod opsin. *Journal of cell science*. 2009; 122(Pt 24):4465–72. [PubMed: 19934218]
61. Sizova OS, Shinde VM, Lenox AR, Gorbatyuk MS. Modulation of cellular signaling pathways in P23H rhodopsin photoreceptors. *Cellular signalling*. 2014; 26(4):665–72. [PubMed: 24378535]
62. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, Lavail MM, Walter P. IRE1 signaling affects cell fate during the unfolded protein response. *Science*. 2007; 318(5852):944–9. [PubMed: 17991856]
63. Espinosa-Diez C, Miguel V, Mennerich D, Kietzmann T, Sanchez-Perez P, Cadenas S, Lamas S. Antioxidant responses and cellular adjustments to oxidative stress. *Redox biology*. 2015; 6:183–97. [PubMed: 26233704]
64. Sopha P, Kadokura H, Yamamoto YH, Takeuchi M, Saito M, Tsuru A, Kohno K. A novel mammalian ER-located J-protein, DNAJB14, can accelerate ERAD of misfolded membrane proteins. *Cell structure and function*. 2012; 37(2):177–87. [PubMed: 23018488]
65. Tashiro E, Zako T, Muto H, Ito Y, Sorgjerd K, Terada N, Abe A, Miyazawa M, Kitamura A, Kitaura H, Kubota H, Maeda M, Momoi T, Iguchi-Ariga SM, Kinjo M, Ariga H. Prefoldin protects neuronal cells from polyglutamine toxicity by preventing aggregation formation. *The Journal of biological chemistry*. 2013; 288(27):19958–72. [PubMed: 23720755]
66. Takano M, Tashiro E, Kitamura A, Maita H, Iguchi-Ariga SM, Kinjo M, Ariga H. Prefoldin prevents aggregation of alpha-synuclein. *Brain research*. 2014; 1542:186–94. [PubMed: 24511594]
67. Abe A, Takahashi-Niki K, Takekoshi Y, Shimizu T, Kitaura H, Maita H, Iguchi-Ariga SM, Ariga H. Prefoldin plays a role as a clearance factor in preventing proteasome inhibitor-induced protein aggregation. *The Journal of biological chemistry*. 2013; 288(39):27764–76. [PubMed: 23946485]
68. Kumar A, Baycin-Hizal D, Shiloach J, Bowen MA, Betenbaugh MJ. Coupling enrichment methods with proteomics for understanding and treating disease. *Proteomics. Clinical applications*. 2015; 9(1-2):33–47. [PubMed: 25523641]
69. Pankow S, Bamberger C, Calzolari D, Martinez-Bartolome S, Lavalley-Adam M, Balch WE, Yates JR 3rd. F508 CFTR interactome remodelling promotes rescue of cystic fibrosis. *Nature*. 2015; 528(7583):510–6. [PubMed: 26618866]
70. Mears AJ, Kondo M, Swain PK, Takada Y, Bush RA, Saunders TL, Sieving PA, Swaroop A. Nrl is required for rod photoreceptor development. *Nat. Genet.* 2001; 29(4):447–52. [PubMed: 11694879]
71. Mustafi D, Kevany BM, Genoud C, Okano K, Cideciyan AV, Sumaroka A, Roman AJ, Jacobson SG, Engel A, Adams MD, Palczewski K. Defective photoreceptor phagocytosis in a mouse model of enhanced S-cone syndrome causes progressive retinal degeneration. *FASEB J.* 2011; 25(9):3157–76. [PubMed: 21659555]
72. Mustafi D, Maeda T, Kohno H, Nadeau JH, Palczewski K. Inflammatory priming predisposes mice to age-related retinal degeneration. *The Journal of clinical investigation*. 2012; 122(8):2989–3001. [PubMed: 22797304]
73. Chen Y, Palczewski K. Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders. *Annu Rev Pharmacol Toxicol*. 2016; 56:273–98. [PubMed: 25839098]
74. Chen Y, Palczewska G, Masuho I, Gao S, Jin H, Dong Z, Gieser L, Brooks MJ, Kiser PD, Kern TS, Martemyanov KA, Swaroop A, Palczewski K. Synergistically acting agonists and antagonists of G protein-coupled receptors prevent photoreceptor cell degeneration. *Sci Signal*. 2016; 9(438):ra74. [PubMed: 27460988]

75. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.* 2002; 30(1):207–10. [PubMed: 11752295]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.

Immunofluorescence and image analysis of NIH3T3 cells expressing GFP and opsins. Panel A, only GFP was expressed; panel B, WT opsin and GFP were co-expressed; panels C-F, P23H opsin mutant and GFP were co-expressed; GFP, Cy3 labeling associated with 1D4 anti-rhodopsin antibodies and nuclei stained with DAPI are shown in green, yellow, and blue, respectively. Cells were treated with 0.05% DMSO in A-C; 5 μ M of compound 1 in D; 10 μ M of compound 2 in E; and 5 μ M compound 1 plus 10 μ M of compound 2 in F. Arrows in B-F indicate opsin (WT or P23H) staining in the ER region. Scale bar, 20 μ m.

Quantification of opsin on the plasma membrane (G) and in the ER region (K) by image based analysis. Unlike WT opsin stained on the cell boundary, the P23H opsin mutant accumulated in the perinuclear region of NIH3T3 cells. Treatment with compound 1 reduced the perinuclear accumulation of P23H opsin, whereas treatment with compound 2 induced a

significant amount of plasma membrane staining of P23H opsin. Co-treatment with both compounds 1 and 2 demonstrated a synergistic rescue of P23H opsin transport to the plasma membrane. For image analysis, the cytoplasm was defined by GFP fluorescence whereas the nucleus was defined by DAPI fluorescence. The MEM-total was calculated as the mean ratio of Cy3 intensity on the plasma membrane region to that in the entire cell. The ER-total was calculated as the mean ratio of Cy3 intensity in the perinuclear region to that in the entire cell. NIH3T3 cells expressing P23H or WT opsin were treated with 0.1% DMSO as controls (G and K). NIH3T3 cells expressing the P23H opsin were treated with compound 1 (H and L), compound 2 (I and M) or compound 2 with 5 μ M compound 1 (J and N); each compound was tested in 10 concentrations starting at 20 μ M and followed by 2-fold dilutions. Data points and error bars represent averages and standard deviations of biological replicates.

Figure 2.

Transcriptome overview of NIH3T3 cells expressing GFP and opsin under different treatment conditions: Control, only GFP was expressed; Opsin, opsin and GFP were co-expressed; P23H, P23H opsin mutant and GFP were co-expressed. Cells were treated with 0.05% DMSO as a vehicle control. T1 or T2, the P23H opsin and GFP expressing cells were treated with 5 μ M of compound 1 or 10 μ M of compound 2, respectively. A. Principle component analysis plot of the five sample groups. B. FPKM reads of *Rho* transcripts from three NIH3T3 stable cell lines revealed similar heterologous expression levels of WT opsin or the P23H opsin mutant in each cell line. Each sample group contained three biological replicates. C. Comparison of differential expression (DE) profiles of Opsin *versus* Control and P23H *versus* Control. The two circles represent each of the two DE profiles. The number of transcripts located in both DE profiles is shown in the overlapping area of the two circles, whereas the number of transcripts detected in only one DE profile is placed in the corresponding circle. The DE filter was set for fold changes of more than 2 and an FDR smaller than 5%.

Figure 3.

Transcriptome changes in NIH3T3 cells from heterologous expression of mouse opsin. Control, NIH3T3 cells expressing only GFP; Opsin, NIH3T3 cells expressing both opsin and GFP. A. Volcano plot of transcripts which showed DE in Opsin *versus* Control. *P* values are plotted in a $-\log_{10}$ format as y-values, and fold changes of FPKM reads in P23H *versus* Opsin are plotted in a Log_2 format as x-values. Representative transcripts that showed significant differential expression are labeled with gene names. B. Pie chart showing biological processes (BP) enriched in the DE profile of Opsin *versus* Control. The size of

each pie is correlated with number of genes included in the corresponding BP as a percentage of the total number of genes counted in all BPs.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 4.

Transcriptome differences between NIH3T3 cells expressing the P23H opsin mutant *versus* those expressing WT opsin. Control, NIH3T3 cells expressing only GFP; P23H, NIH3T3 cells expressing both the P23H opsin mutant and GFP; Opsin, NIH3T3 cells expressing both opsin and GFP. A. Volcano plot of transcripts which showed DE in P23H *versus* Opsin. *P* values are plotted in a $-\log_{10}$ format as y-values, and fold changes of FPKM reads in P23H *versus* Opsin are plotted in a $\log_2$ format as x-values. Representative transcripts that showed DE in P23H *versus* Opsin but not in P23H *versus* Control are in black print,

suggesting loss-of-opsin-properties in the P23H opsin mutant. Those that showed DE in both P23H *versus* Opsin and P23H *versus* Control are indicated in red, suggesting gain-of-abnormal-properties in the P23H opsin. B. FPKM reads of transcripts in the endoplasmic reticulum associated protein degradation (ERAD) pathway of the three stable cell lines. The results suggest no significant activation of this pathway due to expression of WT or P23H opsin. Each sample group had three biological replicates.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 5.

Transcriptome shift of NIH3T3 cells expressing P23H opsin and GFP upon treatment with compound 1 (T1 *versus* P23H). A. Heat map of transcripts showing DE in T1 *versus* P23H. Four sample groups are shown, each with three biological replicates: grey bar, Control - NIH3T3 cells expressing only GFP; green bar, Opsin - NIH3T3 cells expressing both opsin and GFP; magenta bar, P23H - NIH3T3 cells expressing both P23H opsin mutant and GFP; blue bar, T1 - NIH3T3 cells expressing both P23H opsin mutant and GFP that were treated with 5 μ M of compound 1. The heat map legend is displayed at the bottom. B. Heat map of transcripts in DE of T1 *versus* P23H that were reversed as compared to their changes in DE of P23H *versus* Opsin. C. Pie chart of biological processes (BP) which were enriched with up-regulated genes are denoted in red and BPs associated with down-regulated genes are denoted in blue. Numbers of genes changed in each BP are shown as a percentage of the total gene number of all BPs represented by the size of the corresponding pie. D. Pie chart of BPs enriched among the 117 genes that were reversed in DE of T1 *versus* P23H compared to their changes in P23H *versus* Opsin. The percentage numbers in parenthesis following each BP represent the percentage of transcripts among the 117 genes classified in that BP. Gene names of the top 25 up- and down-regulated transcripts are labeled at the side of each BP. BPs that are most relevant to opsin biosynthesis are labeled in bold. Transcripts that were selected and confirmed by qPCR assay were labeled in bold.

Figure 6.

Fold changes of 9 transcripts in NIH3T3 cells expressing GFP only (Control, grey), Opsin and GFP (Opsin, green), or P23H opsin and GFP treated with DMSO (P23H, magenta) or compound 1 (DMSO), quantified by qPCR. Fold changes of transcripts were first normalized by *Gapdh* as a control transcript, and then compared to Control in the qPCR assay. The fold change of each transcript was averaged from three biological replicates, and error bars show the standard deviations of those replicates. * indicates a *P* value smaller than 0.05. Transcriptional regulation of the 9 transcripts by T1 was in agreement with what was found by RNA-seq.

Table 1

The number of sequencing reads generated for each sample and their alignment statistics. The alignment statistics refer to the number and percentage of reads that align to the genome and to the annotation used in the analysis. Reads mapping to the genome assembly but not the annotation are from intergenic, intronic, or novel transcripts not present in the annotation.

Samples	Total Reads	Assembly	Annotation	% Genome	% Assembly
Control.1	30,452,046	27,923,900	25,058,876	91.7	82.3
Control.2	26,566,098	24,353,828	21,365,196	91.7	80.4
Control.3	24,620,210	23,212,126	20,288,806	94.3	82.4
Opsin.1	41,396,766	37,892,165	34,548,292	91.5	83.5
Opsin.2	26,478,896	24,207,557	21,314,236	91.4	80.5
Opsin.3	46,300,468	43,618,647	37,763,672	94.2	81.6
P23H.1	30,715,732	28,228,632	25,307,996	91.9	82.4
P23H.2	40,926,422	37,480,508	34,042,686	91.6	83.2
P23H.3	32,057,578	30,168,399	26,602,622	94.1	83.0
T1.1	21,895,902	19,480,527	17,761,142	89.0	81.1
T1.2	23,551,414	21,054,805	18,928,522	89.4	80.4
T1.3	33,157,974	30,313,499	26,632,680	91.4	80.3
T2.1	31,953,284	29,212,898	26,769,282	91.4	83.8
T2.2	45,090,996	41,511,166	37,576,600	92.1	83.3
T2.3	46,026,166	43,463,234	37,740,812	94.4	82.0

Table 2

List of cAMP responsive elements (CRE)-containing genes with their transcripts differentially expressed in NIH3T3 cells expressing opsin and GFP compared to those expressing GFP only (Opsin *versus* Control). Cutoff: Fold change >2 or <0.5, *P* value<0.05.

Gene name	Transcript name	Description	Log2(Fold Opsin <i>versus</i> Control)	<i>P</i> value (Opsin <i>versus</i> Control)
Gsta4	Gsta4-201	glutathione S-transferase, alpha 4	1.08	7.76E-08
Pcx	Pcx-201	pyruvate carboxylase	-1.31	2.65E-05
Pdk4	Pdk4-001	pyruvate dehydrogenase kinase, isoenzyme 4	-1.61	5.73E-08
Per1	Per1-001	period circadian clock 1	-1.15	2.26E-04
Per1	Per1-003	period circadian clock 1	-1.06	1.86E-03
Pparg c1a	Ppargc1a-001	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	1.85	7.63E-06
Egfr	Egfr-001	epidermal growth factor receptor	-1.19	5.98E-08
Pr12c2	Pr12c2-201	prolactin family 2, subfamily c, member 2	7.27	9.85E-07
Inhba	Inhba-202	inhibin beta-A	-1.08	2.34E-03
Ppp1r15a	Ppp1r15a-001	protein phosphatase 1, regulatory (inhibitor) subunit 15A	-1.10	6.93E-05

Table 3

List of transcripts enriched in the vesicle transport pathway that revealed the same trends of differential expression when comparing P23H *versus* Control and Opsin *versus* Control. Cutoff: Fold change >2 or <0.5, *P* value<0.05.

Gene name	Transcript name	Description	Log2(Fold P23H <i>versus</i> Control)	<i>P</i> value (P23H <i>versus</i> Control)	Log2(Fold Opsin <i>versus</i> Control)	<i>P</i> value (Opsin <i>versus</i> control)
Klc1	Klc1-004	kinesin light chain 1	1.50	2.74E-03	1.33	1.04E-02
Stx16	Stx16-001	syntaxin 16	-1.06	3.54E-03	-1.22	1.40E-02
Stx16	Stx16-201	syntaxin 16	1.36	5.32E-03	1.34	3.22E-02
Kif1c	Kif1c-005	kinesin family member 1C	1.83	1.31E-04	1.30	2.36E-02
Myo7a	Myo7a-001	myosin VIIA	1.14	5.00E-05	1.03	9.53E-03
Dlg4	Dlg4-001	discs, large homolog4 (Drosophila)	-1.19	2.36E-05	-1.50	2.44E-02
Lrp8	Lrp8-003	low density lipoprotein receptor-related protein 8, apolipoprotein e receptor	1.36	2.43E-04	1.54	2.82E-03

Table 4

Mean FPKM reads of transcripts involved in the endoplasmic reticulum associated degradation (ERAD) pathway of NIH3T3 cells expressing GFP (Control), Opsin/GFP (Opsin), or P23Hopsin/GFP (P23H). Mean FPKM reads were calculated from 3 biological repeats.

Gene name	Transcript name	Description	Mean FPKM reads		
			Control	Opsin	P23H
Atf4	Atf4-201	activating transcription factor 4	322.7	343.6	323.2
Atf6	Atf6-001	activating transcription factor 6	16.9	14.4	15.5
Calr	Calr-001	calreticulin	262.9	181.4	246.8
Canx	Canx-001	calnexin	285.3	269.4	287.8
Ddit3	Ddit3-001	DNA-damage inducible transcript 3	297.8	113.3	146.7
Dnajb11	Dnajb11-001	DnaJ (Hsp40) homolog, subfamily B, member 11	53.3	46.0	45.8
Dnajb9	Dnajb9-201	DnaJ (Hsp40) homolog, subfamily B, member 9	15.0	13.5	13.1
Edem1	Edem1-201	ER degradation enhancer, mannosidase alpha-like 1	47.1	35.3	39.8
Edem2	Edem2-001	ER degradation enhancer, mannosidase alpha-like 2	18.1	12.4	20.1
Eif2a	Eif2a-001	eukaryotic translation initiation factor 2A	38.7	41.7	33.3
Eif2ak3	Eif2ak3-001	eukaryotic translation initiation factor 2 alpha kinase 3	13.5	14.2	12.1
Ernl	Ernl-001	endoplasmic reticulum (ER) to nucleus signaling 1 (IRE1)	16.8	11.2	13.0
Hsp90b1	Hsp90b1-001	heat shock protein 90, beta (GRP94), member 1	382.8	267.3	347.5
Hspa4	Hspa4-001	heat shock protein 4	64.8	101.7	95.2
Hspa5	Hspa5-001	heat shock protein 5	391.6	292.0	394.9
Vcp	Vcp-001	valosin containing protein	153.7	228.5	201.1

Table 5

Fold change of transcripts comparing NIH3T3 cells expressing the P23H opsin and GFP that was treated with compound 1 and those treated with DMSO (T1 *versus* P23H).

Gene name	Description	RNA-seq		qPCR	
		Fold change (T1 <i>versus</i> P23H)	P value (T1 <i>versus</i> P23H)	Fold change (T1 <i>versus</i> P23H)	P value (T1 <i>versus</i> P23H)
Txnip	thioredoxin interacting protein	9.44	4.12E-13	15.63	2.32E-03
Nqo1	NAD(P)H dehydrogenase, quinone 1	2.55	1.68E-06	2.60	4.14E-02
Gstp1	glutathione S-transferase, pi 1	2.43	4.98E-06	8.92	8.29E-03
Pfdn6	prefoldin subunit 6	4.25	4.20E-03	5.36	1.89E-02
Itch	itchy, E3 ubiquitin protein ligase	0.48	1.29E-03	0.54	4.81E-02
Vdr	vitamin D receptor	3.33	5.86E-09	4.44	7.59E-04
Dnajb14	DnaJ (Hsp40) homolog, subfamily B, member 14	1.49	2.19E-09	16.09	3.00E-02
Clec16a	C-type lectin domain family 16, member A	2.46	2.00E-03	1.86	2.93E-02
Masp1	mannan-binding lectin serine peptidase 1	0.22	3.34E-07	0.61	4.98E-02